Proton pump inhibitor use and cancer mortality

Proton pump inhibitors (PPIs) are commonly used as a supplement to cancer therapy. Yet, their effect on cancer mortality is largely unknown. Using data from Danish nationwide registries and Cox models regressing of both propensity scores and drug use, we estimated hazard ratios (HRs) with 95% confidence intervals (CIs) for cancer‐specific and noncancer death among PPI users (≥2 prescriptions within six months after diagnosis; n = 36,066)...